Urologia Internationalis
Original Paper
Increased Expression of EZH2, a Polycomb Group Protein, in Bladder CarcinomaArisan S.a · Buyuktuncer E.D.b · Palavan-Unsal N.b · Çaşkurlu T.a · Çakir O.O.a · Ergenekon E.aaSisli Etfal Research and Training Hospital, 1st Urology Clinic Sisli, Istanbul and bHalic University, Science and Literature Faculty, Molecular Biology and Genetics, Istanbul, Turkey
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: November 23, 2004
Accepted: June 17, 2005
Published online: October 05, 2005
Issue release date: October 2005
Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 4
ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)
For additional information: https://www.karger.com/UIN
Abstract
Introduction: Recent experiments have demonstrated that polycomb group gene enhancer zeste homolog 2 (EZH2) is highly expressed in many cancer types. Therefore, we aim to demonstrate EZH2 gene expression in transitional cell bladder cancer. Patients and Methods: The reverse transcriptase-polymerase chain reaction (RT-PCR) was used for detection of EZH2 mRNA levels in healthy and cancerous human bladder specimens. Also, expression of the particular protein was determined by Western blotting and immunohistochemistry to confirm RT-PCR results. Results: Gradually increased expression of EZH2 was detected by mRNA and protein levels in highly advanced bladder cancer specimens. In contrast, 100% of control subjects were negative for EZH2 expression. The expression of EZH2 was more frequent in G3 (92%) than G1-G2 (62–63%) and more frequent in T1-2 (72–85%) than Ta (56%). Western blot analysis results confirm the RT-PCR results. Conclusions: EZH2 overexpression precedes high frequencies of proliferation and the gradual advance of bladder cancer. These observations suggest that deregulated expression of EZH2 is associated with bladder carcinoma.
© 2005 S. Karger AG, Basel
Related Articles:
References
- Varambally S, Dhanasekeran SM, Zhou M, Barette TR, Kumar Sinha G, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM: The PcG group of protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624–629.
- Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K: EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003;22:5323–5235.
- Cardoso C, Mginon C, Hetet G, Grandchamps B, Fontes M, Colleaux J: The human EZH2 gene: genomic organization and revised mapping in 7q35 within a critical region of malignant disorders. Eur J Hum Genet 2000;8:174–180.
- Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA: Multiplex biomarker approach for determining risk of prostate-specific antigen defined recurrence of prostate cancer. J Natl Cancer Inst 2003;95:661–667.
- Raaphorst FM, Meijer CJLM, Fieret E, Blokzijl T, Mommers E, Buerger H, Packeinsen J, Sewalt RGAB, Otte AP, van Diest PJ: Poorly differentiated breast carcinoma is associated with increased expression of human polycomb group EZH2 gene. Neoplasia 2003;5:481–488.
- Kirmizis A, Bartley SM, Farnham PJ, Visser HP, Gunster MJ, Kluin-Nelemans HC, Manders EM: Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol Can Ther 2003;2:113–121.
- Raaphorst FM, Meijer CJ, Willemze R, Otte CJ: The polycomb group protein EZH2 upregulated in proliferating, cultured human mantle cell lymphoma. Br J Heamatol 2001;112:950–958.
- Raghavan D, Skinner E: Genitourinary cancer in the elderly. Semin Oncol 2004;31:249–263.
- Bradford M: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–254.
- Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RGAB, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM: EZH2 is a marker of aggressive breast cancer and promoter neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003;100:11606–11111.
- Sellers WR, Loda M: The EZH2 polycomb transcriptional repressor – a marker or mover of metastatic prostate cancer? Cancer Cell 2002;2:349–350.
- Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V: Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 2004;23:5759–5769.
- Fukuyama T, Otsuka T, Shigematsu H, Uchida N, Arima F, Ohno Y, Iwasaki H, Fukuda T, Niho Y: Proliferative involvement of ENX-1, a putative human PcG group gene, in haematopoietic cells. Br J Haematol 2000;108:842–847.
- Sewalt RGAB, van der Vlag J, Gunster MJ, Hamer KM, den Blaauwen JL, Satjin DPE, Hendrix T, van Driel R, Otte AP: Characterization of interactions between the mammalian polycomb group proteins Enx1/EZH2 and EED suggest the existence of different mammalian polycomb-group protein complexes. Mol Cell Biol 1998;18:3586–3595.
- Raaphorst FM, Otte AP, Meijer JLM: PcG group genes as regulators of mammalian lymphopoiesis. Trends Immunol 2001;22:682–689.
- Raaphorst FM, van Kemenade FJ, Blokzijl T, Fieret E, Hamer KM, Satjin DP, Otte AP, Meijer CJ: Coexpression of BMI1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin’s disease. Am J Pathol 2000;157:709–715.
- Van Veer LJ, Dai H, van de Vijver HJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witheeven AT: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530–536.
- Jacobs JJ, van Lohuizen M: PcG repression: From cellular memory to cellular proliferation and cancer. Biochim Biophys Acta 2002;1602:151–161.
Article / Publication Details
Received: November 23, 2004
Accepted: June 17, 2005
Published online: October 05, 2005
Issue release date: October 2005
Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 4
ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)
For additional information: https://www.karger.com/UIN
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
